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1. INTRODUCTION 
a 
Cancer of the cervix is the ~~qnd cause of cancer deaths among females in Malaysia after 
breast cancer. Penang, a state which has an up to date cancer registry records an annual 
inc~dence of 16 cases per 100,000 ~es. For the past twenty years or so Annual Reports 
of Ministry of Health recorded an average of 2200 new cases per year (Ministry of Health 
Annual Reports 1980-2000). This number is higher than the speculated 16 cases per 100,000 
females in this country where the population of females is about 10.5 million 
Cancer of the cervix is a preventive disease as the precursor cancer cells can be easily 
detected provided the women do regular screening tests called Pap Smear. The etiology is 
Human Papilloma Virus (HPV) in most cases and although there are ways to prevent 
transmission of the organisms, this is not often possible as the infection in the males are 
mainly asymptomatic. 
Like other cancers, cancer of the cervix is graded according to its cellular differentiation. 
Several prognostic features recorded in the literature include the specific aggressive HPV 
strains, the angiogenetic factors, the small cell type and the presence of oncogene 
expressions at molecular level. In Malaysia, study on cancer of the cervix has been patchy 
and incomprehensive. With this in mind, we embarked on this study entitled " Detection by 
In sHu hybridization of specific high risk HPV In archival tissue of lnvas1ve cervical carcinoma 
and cervical lntraeplthellal neoplasia using specific blotynylated HPV DNA probe In 
conjunction with P53 and Rb gene protein expression". This study comprises 2 parts; 
Identification of tumour suppressor genes, p53 and Rb gene in cervical lesions and 
identifying HPV subtypes in cervical cancer using in situ hybridization. 
The identification of HPV by in situ hybridization did not materialize due to technical 
difficulty. We were not able to get any lesions positive although the HIE showed good 
koilocytic atypia. We are reporting here the findings of the first part of the research. 
Clinicopathology of cervical tance:rs 
Cervical Intraepithelial Lesion or CIN is a non invasive cervical lesion which demonstrates 
defective squamous cell maturation and differentiation. Depending on the thickness of this 
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defective maturation and differentiation, they are called ClN 1 when only a third of the cervical 
epithelium is involved. CIN 11 changes is when two third of the epithelium is involved and CIN 
·- . ll!..~~~l:!.th~.~~Ql~-~ckne$$.Qfthe epithelium is involved. This is the nomenclature widely used 
by histopathologists worldwide. Bethesda classification, is the classification employed by 
cytologists and cytopathologists for ~ological diagnosis. The comparison between these 
classifications is illustrated below {Table 1 ). 
Table 1: Terminologies for cervical cancer precursor lesions 
WHO 
:rv.fild Dysp~ia (CIN I) 
Moderate Dysplasia (CIN ll) 
(HSIL) 
Severe Dysplasia (CIN ill ) 
WHO: World Health Organisation 
Bethesda System 
Low Grade Squamous Intraepithelial Lesion (LSIL) 
High Grade Squamous Intraepithelial Lesion 
There is an orderly program of maturation and differentiation throughout the epithelial thickness 
both at the morphological and at the mol~cular level (Stoler 1997). In an HPV infected cell, this 
orderly maturation does not occur. The infected cells are unable to divide. The viral DNA Early 
Region is detected within the suprabasal zone, and as the cell differentiates and approaches 
maturation there will be an induction in the synthesis of all viral genes and viral DNA. The 
production of virions will accumulate in the cells just beneath the uppermost epithelial surface. 
Such lesions are recognized as LSIL (Low Grade Intraepithelial Lesions) or mild dysplasia 
The HPV has many Early Regions and these are coded as E1 to E7. The nuclear enlargement and 
hyperchromasia that is recognized histologically as atypia, is the result of E6/E7 HPV 
oncoprotein-mediated activation of host DNA synthesis. The appearance of koilocytes is 
strongly associated with the presence of HPV E4 cytokeratin binding protein in an infected cell. 
Unlike the LS~, the HS~ (High Grade Intraepitbelial Lesion)does not attain a coordinate link 
between differentiation and viral early gene expression. The actual mechanism is unknown. 
Speculated mechanisms include viral integration or mutation in HPV E2, such that E2 -
controlled regulation of E6/E7 expression is lost. This lead to loss of squamous cell 
differentiation and maturation morphologically seen as dysplasia. 
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These dysplastic cells are genetically unstable. They are at a greater risk of acquiring additional 
... genetic. errors ... In . .an appropriate environmental milieu.--and under the.,inflaence ef -external 
mutagens, these cells can progress to malignant transformation 
Cervical Carcinoma In General 
There are estimated 40,000 cases of new invasive cervical cancers annually and nearly 1 million 
preinvasive (dysplastic/C1N/LS~IHSIL) lesions .The World Health Organization (WHO) in 
collaboration with International Society of Gynaecological Pathologists classify cancer of the 
cervix as in table 2 below 
Table 2. Modified World health Organization histological classification ·or epithelial tumours of 
the uterine cervix 
Squamous cell carcinoma 
Microinvasive squamous cell carcinoma 
Invasive squamous cell carcinoma 
Verrucous carcinoma 
Warty ( condylomatous) carcinoma 
Papillary squamous cell ( transitional ) carcinoma 
Lymphoepithelioma-like carcinoma 
Adenocarcinoma 
Mucinous adenocarcinoma 
Endocervical type 
Intestinal type 
Signet-ring type 
Endometrioid adenocarcinoma 
Endometrioid adenocarcinoma with squamous metaplasia 
CleB· cell adenocarcinoma 
Minimal deviation adenocarcinoma 
Endocervical type ( adenoma malignum) 
Endometrioid type 
Serous adenocarcinoma 
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Mesonephric carcinoma 
Well differentiated villoglandular adenocarcinoma 
__ Q~er ~p~th~UalJ;umpurs_ ---~ - :.---. -·- ·--··· ~--- - ··---..-. ·· · 
Adenosquamous carcinoma 
Glassy cell carcinoma 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Adenoidbasal carcinoma 
Carcinoid-like tumour 
Small cell carcinoma 
Undifferentiated carcinoma 
The peak incidence of invasive cervical cancer occurs at age 40-45 years and 10 years younger 
for pre-invasive lesions (Crum, 1999). This cancer is highly associated with onset of sexual 
activity and HPV infection, acquired through sexual intercourse. (Crum,l999). HPV as the 
causative agent of more than 95% of cancer of the cervix is undisputed. There are numerous 
studies supporting this deduction. 
Ferrera eta!. (1999) employed general primer mediated PCR followed by PCR based sequencing 
technique to detect HPV DNA. They confirmed th~t HPV DNA was detected in 87o/o of all 
preinvasive and 95% of invasive cancers. In the control group of women, only 39% were 
positive for HPV DNA. They showed that HPV 16 ranked highest in pre-invasive, invasive 
cancers and in control group. Walboomers et al. (1999) utilized PCR-based test, deduced that, 
HPV prevalence in cervical carcinomas is close to 99. 7o/o. Thus, it can be inferred that the cause 
of cervical cancer is infection by HPV. 
Prevention of cervical cancer focuses on educating women on the strong causal link of HPV 
infection and the development of cervical cancer. One of the way is encouraging them to modify 
their sexual behaviom (Sidawy, 1997). Cervical carcinoma can, in theory, be prevented and 
treated by HPV vacc.uie therapy. HPV vaccine is still at the research phase. Therapeutic vaccines 
would eliminate HPV infection through cell mediated mechanisms, whereas prophylactic 
vaccines would act by inducing. antivirion antibodies that prevent the infection. The prospect of 
effective vaccines is particularly appealing in countries in which massive cervical screening is 
not possible due to lack of funds.Three (3) HPV 18 E6 derived peptides (ELTEVFEFA, 
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KTVLELTEV and KLPDLCTEL) have been identified. The E7 derived peptide (TLQDIVLID..,) 
was found to be highly immunogenic and could react against purified human CDS+ T cells 
(Rudolfet all, 2001). 
Imm.unocompronlised states such as ~ promote HPV infection. As mv infection rates rises, 
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the increase in cervical cancer rates is expected. Frequent and stringent screening protocols and 
incorporation of adjunct screening modalities eg: tumour suppressor marker immunostaining, 
can aid in early and effective detection of cervical lesions in these immunocompromised 
population. Dorucci et al. (200 1 ), examined 483 Italian women (median follow up of 7 years) 
between 1981 - 1995 and observed an increasing trend in the incidence of invasive cervical 
cancers in tandem with the rise of mv related diseases. In Nigeria, where the incidence of HIV 
infection is high, the HPV and CIN prevalence is also high (Thomas 2001) 
The Biology Of Human Papillomavirus 
The Papilloma viruses are members of the Papovavirus family. All viruses of the family have in 
common small, double stranded DNA that replicate in the nucleus and have icosahedral protein 
capsules that form non - enveloped virions. Papilloma viruses have 55 run, diameter capsids with 
8,000 base pairs. The double stranded DNA genome has Early and Late Regions. There are 
seven or eight Early and two Late genetic open reatliiig frames (ORFs), that encode all the gene 
products (Stoler, 1997). 
What is a Papillomavirus 
To date, there are tnore than 100 HPV types. A new HPV type should have less than 
90% sequence homology in selected genomic regions compared to any of the known 
HPV types (Figure 1 ). Broadly speaking, there are cutaneotropic and mucosotropic 
groups ofHPVs. The cutaneotropic HPV viruses cause warts on the upper parts of the 
body. The mucostropic viruses cause the genital lesions. The mucosotropic group, is 
classified into low risk and higl1 tisk HPV s. The low risk viluses are almost never found in 
invasive cancers. The high risk on the contrary, are those most often found in invasive cancers 
(Stoler, 1997). 
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Figure 1. Phylogenetic tree constructed for the mucosoti·opic group of HPVs based on the 
alignment of 384 nucleotides in the HPV E6 genes. The most common related pathologies are 
listed on the right. (Figure 1 ). 
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Functions of Viral On co proteins And Their Interactions With Cellular Proteins 
HPV genomes codes for at least six different Early (E) and two Late (L) proteins ( Zur Hausen 
2000). Table 3 summarizes the functions of the different open reading frames of Human 
Papilloma virus (Arends et al, 1998 and Corden et al, 1999 ). High risk HPVs code for at least 3 
proteins for growth stimulating and transforming proteins. These are ES, E6 and E7 (Zur 
Hausen, 2000). 
Table 3 : Regulation of different open reading frames of Human Papillom.av1rus 
Open Reading Regulation and functions 
Frames (ORF) 
EI Negative regulators of replication 
E2 Main viral transcription regulator 
E3 Nonspecified 
E4 Produces Jate cytoplasmic protein 
E5 Early expansion protein of an infected cell clone 
E6 I. Cause chromosomal instability of an infected host 
2. Cause mutational consequences of a HPV positive host cell 
3. Eliminate p53 gene 
E7 1. Bind to .Rb gene and Rb related pocket proteins 
2. Enhance phosphorylation and degradation via ubiquination. 
3. Regulate proliferation of cells infected by high risk HPV 
ES Nonspecified 
LI Regulator of major capsid protein 
L2 Regulator of major capsid protein 
The Mechanism of Cervical Carcinogenesas 
HPV infection plays a major role in cervical carcinogenesis. lligh risk HPV is consistently found 
in over 90% of cervical cancers and they possess transforming viral oncogenes (E6 and E7). The 
main mechanism of action is reduction of tumom suppressor genes p53 and the Retinoblastoma 
7 
!· 
• 
(Rb) gene of the .host c~lls. This is done by the E6 and E7 oncoproteins of the high risk HPV 
subtypes 16 and 18. The low riskHPV such as HPV6b or 11 do not exbib~t such action (Arends 
et al, 1998). 
Degradation of tumour suppressor p53 is mediated by E6 or E6-AP (E6 Associated Protein) 
ligase The close interaction between E6~6-AP is potentially important in the recent observation 
of E6-AP mediated ubiquinati.on and degradation of the src family tyrosine kinase Blk. The 
presence of E6 paradoxically blocks this degradation and thereby stabilizes the respective kinase 
and stimulates mitotic activity with consequent neoplastic growth. 
Similar to the functions of E6, E7 also binds to Rb - related pocket proteins. This binding results 
in phosphorylation of Rb proteins and subsequently enhances degradation by ubiquination. 
Following this molecular event, there will be release of transcription factors of the E2F family, 
which activates the cell's proliferative activity. Excessive uncontrolled cellular proliferation will 
result in n~plastic transformation (Zm Hansen, 2000). Integration of viral E6 and E7 
oncoproteins are the key factor in cervical carcinogenesis (Figure 2) 
Figure 2 : Diagrammatic representation of the region of the subgenomic fragments of high risk 
HPV created by restriction endonuclease digestion. The shaded region of the genome is that 
believed to be present after viral DNA integration . 
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Loss of p53 and Rb gene functions via rapid degradation by HPV E6 and E7 oncoproteins 
respectively, leads to loss of cell cycle growth regulation particularly within the transit phase, 
Go/Gl to S (Bahr 1997,.Arends eta/. 1998) (Figure 3). 
Figure 3: Integration ofHPV in ~11 cycle 
.. ' 
4Jf!t;IDIIft oncoproteins 
rendering loss 
of cell cycle 
control 
The inner cycle (refer figure 3) divides the life of the cell into periods of interphase and cell 
division. At the end of G1 , one of the daughter cell, may continue to point R, the restriction 
point, ready to begin the DNA synthesis necessary for subsequent cell division. This is also a 
trigger point where a protein kinase has associated with a specific cyclin to initiate the DNA 
synthesis. In the S phase DNA is primarily synthesized. The product of this synthesis is sort out 
9 
at G2. Here again a cyclin dependant protein kinase(Cdlc), with a specific cyclin, triggers theM 
phase. The mitotic events comprises of prophase, metaphase, anaphase and lastly, telophase, 
Tumour suppressor gene, p53 also acts as a " guardian of the genome " and is involved in 
responding to DNA damage by inducing_ either growth arrest or cell death by apoptosis (Figure 
• ' 
4). Thus, HPV mediated loss of p53 function decreases the cancer cell' s susceptibility to 
apoptosis. This promotes cellular survival. These cells have, abnormal and unstable genetic 
make up thus may transform to malignant cells (Arends et al, 1998). 
Figure 4: Schematic representation of apoptosis (Cotran et al, 1999) 
NORMAL 
NECROSIS 
Apopto!lc 
bodY 
APOPT0$1$ 
The sequential ultrastructural changes seen in coagulation necrosis (left) and apoptosis 
(right). In apoptosis, the initial changes consists of nuclear chromatin condensation and 
fragmentation, followed by cytoplasmic budding and phagocytosis of the extruded 
apoptotic bodies. 
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There is a preferential integration site within both the host and viral genomes (Carden et al. 
1999). The site of HPV 18 DNA integration in a cell line derived from an HPV 18 DNA 
1positive cervical carcinoma has been localized to chromosomes 8q24 and 2p24. The 
chromosomes positions 8q24-qter and 2!223·24 coincide with the location of c-myc and N-myc, 
4' 
respectively. The c-myc oncogene induces uncontrolled cellular proliferation and inactivates p53 
gene thus reducing apoptosis (Soengas eta/, 1999). 
p53 tumour suppressor gene 
P53 is a tumour suppressor gene. Abnormalities ofp53 have been found to be the commonest 
molecular abnormality occurring in a wide range of human cancers. The loss of genetic 
information at the 17p locus where p53 gene is located is common in all neoplasia Forty (40%) 
of the malignant tumours show detectable p53 abnormality. The most frequent is malignant 
melanoma (88%), testicular tumour (87%) and colorectal carcinoma (58o/~). Lower in the list are 
leukaemias (13%) and thyroid tumours (5%) (Dowell & Hall, 1994). The relationship of DNA 
and p53 is as follows : 
a) DNA viruses including HPV, produces proteins that bind to and functionally inactivate 
p53 protein. 
b) Wild type p53 possesses tumour suppressor activity, while the mutant protein does not 
c) Wild type p53 can induce cell cycle arrest, a property lost by mutant protein 
d) Wild type p53 protein can bind DNA in a sequence specific manner, whereas mutant 
p53 protein cannot, indicating that p53 is probably a transcriptional regulator 
e) Abnormalities ofp53 are common in neoplasia 
f) Mutation of p53 gene is associated with conformational changes and altered protein 
stability 
g) P53 has a role in apoptosis, particularly after genotoxic insults 
Detection of p53 aberrations in normal cells could indicate likely transformation of the cell into 
neoplasia and its detection in neoplastic cells could predict \the aggressiveness of the cancer 
Detection of p53 
p53 abnormalities can be detected at chromosomal, gene and at protein level. For this study we 
utilized immunohistochemical method to detect p53 gene mutation at the protein level. The 
abnormal p53 protein or the mutant p53 is more stable than the wild type fonn (Rabah et al, 
2000). The degraded p53 is a functional equivalence of a mutated p53 (Stoler, 1997). This result 
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in abnormal protein accumulating to levels where it can be detected by immunohistochemistry. 
This technique is fairly rapid and economical to be used in screening for p53 alterations. It can 
. .. _. ···~· .. be .. P~Qm.t~d pn both cytological and histological material either paraffinized or fresh frozen 
tissues (Dwell & Hall, 1994) . 
HPV negative cervical carcinoma 
A small percentage of cervical carcinoma is HPV negative. HPV negative cervical cell lines 
reveals mutation in TP53 gene. The mutation frequency range from Oo/o to 50% among HPV 
negative cervical cancer cell lines compared to HPV positive samples which showed only about 
14% mutation frequency (Helland et al 1998). The site of mutation is mapped at .codon t"81, 
·where a C ~ T transversion occurs leading to an Arginine to Cystein amino acid substitution. 
This knowledge gives the insight that genetic therapy could be developed targeting the specific 
mutation site. 
The level of p53 in cells are regulated by its interaction with Mdm.-2 protein (Prives & Hall, 
1999). Mdm2 is one of the cellular proteins and mdm2 gene is one of the target genes of p53. A 
negative feedback loop exists in which the basal level of p53 activates the basal level of 
downstream target genes including mdm2. Mdm2 protein binds p53, inactivating the ability of 
p53 to function as a transcription factor. This is done by blocking access to the basal 
transcription apparatus and also targeting p53 for ubiquitin - mediated proteolytic degradation. 
Any insult will alter this signaling pathways resulting in alteration of the level and state of p53, 
perturbing the negative feedback loop (Figure 6). Disruption of p53 and mdm-2 interaction in 
vivo by a peptide leads to increased quantities of stabilized p53 (Figure 7) 
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Figure6: The relationship ofp53 and Mdm protein 
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Therefore, not only viral oncoprotein can inactivate p53 other cellular proteins such as Mdm-2, 
~e implicated in p_53 inactiya#Q~. Tbi_~ finding is in;lpo_napt in understanding HPV. negative 
cervical carcinogenesis. 
p53 index could be used as prognostic value by segregating cases into 2 groups of tumours with ' 
high level positivity' where greater than 20% of tumour cells are positive and low level where 
less than 20% of tumour cells are positive This classification is based on widespread over-
expression of p53 in many aggressive cancers. This strongly correlates with molecular 
abnormality of the p53 gene. Contrastingly, a tumour with low percentage of positivity does not 
correlate with the presence of mutation. p53 protein -product expression carries an important 
pathobiological significance as an independent predictor of adverse prognosis [Dowell & Hall 
(1994)]. 
The Rb (Retinoblastoma) gene 
The Rb gene is located near chromosome 13q14.It is necessary for proper differentiation of the 
retinoblasts. The importance of the Rb gene, however goes far beyond retinoblastoma. There is 
good evidence that Rb gene produces an inhibition control on cell proliferation. DNA tumour 
virus transforming proteins such as HPV E7 oncoprotein, can bind and inactivate Rb gene via 
ubiquination and proteolysis (Wynford-Thomas, 1991). Rb gene is found to be inactivated in a 
variety of other cancers, including those of breasts, bladders, osteosarcoma and small cell 
undifferentiated carcinoma of the lung (Chandrasoma (1998). Rb gene is either completely 
absent or has significant deletions in tumours of epithelial origin such as squamous cell 
carcinoma of the head and neck (Stoler 1997) 
Immunohistochemistry as opposed to other molecular methods 
Immunohistochemistry is the method of choice in this study This technique detects the stabilized 
protein resulting from loss-of-function of p53 (Dowell & Hall, 1994). Detection of p53 by 
molecular methods yields lower frequencies of p53 abnormality as compared to immunostaining 
particularly those concerning malignant tumours of the brain, cervix and sarcoma. 
The counting system is based on the scoring system suggested by Dowell & Hall (1994). For 
p53 to be of prognostic value the deduction of positivity index should be divided into a 
high level positivity [more than 20 % of the cells are positively stained] and low level 
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positivity corresp~nding to less than 20 % of the cells are positive stained by 
immunochemistry. Likewise this counting method is applied to Rb gene protein 
We chose the indirect method for both p53 and Rb protein immunohistochemical staining. 
' Robinson (1982) for the advantages below 
a) It has the highest sensitivity as compared to the other methods 
b) The quantity of the primary antibody used is small, thus more cost-effective 
c) The antibody is easily available 
d) The technique is rapid and cost effective 
e) It can be performed on both histological and cytological (frozen and paraffin) 
material. 
Compared to other molecular techniques, immunohistochemistry has superior pick up rate. This 
is because of its ability to detect stabilized protein even if a loss-of-function mu~tion has 
occurred outside the hot-spot region as described by Dowell & Hall (1994). In addition, altered 
p53 protein by alternative mechanisms such as viral oncoprotein induced degradation can also be 
detected by immunohistochemical method. The accuracy of any immunohistochemical analysis, 
depends on the following factors; 
a) The sensitivity of the testing procedure 
b) The detection system used 
c) The optimum antibody dilution achieved 
Common to all immunohistochemistry methods certain technical aspects can influence the final 
results including; 
a) Over fixation causing antigenic loss 
b) Lack of good tissue adhesion to slides causing reduced areas of tissue examined 
c) The efficiency of the antigenic retrieval system 
15 
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2. OBJECTIVES 
General 01ljectives 
a) To perform a laboratory based research on p53 and Rb gene protein products in 
cervical lesions seen at~:;¥ospital Univeristi Sains Malaysia [HUSM], Kubang 
Kerian between 1995 to early 1999. 
b) . To speculate the clinical significance of p53 and Rb gene protein products in 
cervical. lesions. 
Specific Objectives 
a) To detect the presence of twnour suppressor p53 in cervical lesions using 
indirect immunohistochemistry method 
b) To detect Rb protein products in cervical lesions using indirect 
immunohistochemistry method. 
c) To compare and correlate statistically the presence or the absence of the tumour 
suppressor p53 and Rb protein index among different groups of cervical lesions 
studied. 
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3. MATERIAL AND METHODS 
Materials 
This is a retrospective study based on paraffinized archival tissue blocks of cervical biopsies and 
hysterectomy specimens. The demograplij,c data and histopathology examination (HPE) reports 
were obtained from the registry book at the Department of Pathology, Hospital University 
Science Malaysia 
Inclusion Criteria 
1) All cervical biopsies between 1995 to early 1999. 
2) All conventional hysterectomy and Whertheim's hysterectomy specimens between 1995 
to early 1999. 
Exclusion criteria 
Cases excluded from this study were those 
a) in which the paraffin bocks were not available 
b) in which the paraffin tissue blocks did not contain sufficient tissue left for 3 serial 
sections 
Case groupings 
Based on the HPE reports the cases were divided into three groups; the control group, the 
preinvasive group and overt carcinoma The selection process was defined as follows: 
a) The Control group 
All normal, inflammatory and benign lesions such as benign endocervical polyp 
b) The preinvasive group 
All cervical lesions with HPV infection and Cervical Intraepithelial (CIN) lesions. These 
cases were further stratified into LSa and HSIL according to the Bethesda System. The 
LSIL groups contains all HPV infected and CIN 1 cases. The HSIL component 
encompasses the CIN 11 and CIN 111 cases. 
c) The invasive group 
All malignant cervical epithelial lesions. They are further divided into; 
(i) Squamous cell carcinoma. This is further divided into Keratinising Squamous 
Cell Carcinoma [SCCK] and Non Keratinising Squamous Cell Carcinoma 
[SCCNK] 
(ii) Adenocarcinoma and other malignant lesions such as Neuroendocrine 
.carcinoma 
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The Method 
a) Preparation oftisssue sections 
Three (3) serial sections 3-5 micron thick were done for each_case, For each case one section was 
submitted for Hematoxylin & Eosin {HIE) staining. One section for p53 staining using 
immunohistochemistry and the rem~ section for Rb protein using immunohistochemistry. 
The Hematoxylin & Eosin stained sections were examined under light microscopy for 
histological confirmation of the diagnosis recorded in the Pathology Registry book. The sections 
for immunohistochemical staining were mounted on Poly-L- Lysin coated slides 
Immunohistochemical staining reagents 
5 types of immunohistochemical reagents were used in this study 
a. Primary antibody for p53 immunohistochemical staining 
Monoclonal Mouse Anti-Human p53 Protein (DAKO) Code no. M 7001, 
Lot056 
Purified monoclonal antibody of mouse antiserum 
Mouse Ig concentration: 400 mg I L 
Isotype:Ig G 2b, kappa 
Total protein concentration: 13.7 giL 
b. Secondmy antibody for p53 immunohistochemical staining 
Biotinylated Rabbit Anti mouse Immunoglobulins (DAKO) Code No: E 354, Lot 
113 
Biotinylated, affinity isolated rabbit anti Mouse immunoglobulins 
Solvent: 0.01 M phosphate buffer, 0.15 M NaCl, 15 mM NaN3, pH 7.2 
Concentration of Specific Antibodies: 1.2 g I L 
Immunogen : Immunoglobulins, mainly Ig G, isolated from mouse serum. 
c. Primary antibody for Rb gene protein immunohistochemical staining 
Epitope Specific Polyclonal Antibody to Retinoblastoma Protein 
Ab .. No: 346P 
Epitope Designation QKM 
Source and Format: Rabbit Polyclonal Ig G, purified and diluted in PBS, pH 7.6 
Immunogen: A synthetic peptide from the C - terminus coupled to KLH human 
retinoblastoma gene product. 
Specification: Antigen retJ.ieval Glyca Solution is recommended. The suggested 
positive control tissue is colon carcinoma. 
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d: Secondary antibody for Rb gene protein immunohistochemical staining 
Biotinylated Goat Anti Rabbit Immunoglobulins (DAKO) Code No: E 432 
Lot014 
Presentation: Biotinylate<L affinity isolated goat anti rabbit immunoglobulin 
Solvent: 0.01 M phosphate ij~er, 0.15 M Na Cl, 15 mM NaN3, pH 7.2 
Concentration of specific antibodies: 1.0 gIL 
Immunogen:Immunoglobulins, mainly Ig G, isolated from rabbit serum. 
e. StreptABComplex I HRP 
DAKOK377 
The package consists of; 
1 m1 of reagent A (Streptovidin) in 0.01 M phosphate buffer, 0.15 M 
NaCl, 15 mMNaN3, pH 7.2 
1 ml of reagent B (Biotinylated Horseradish Peroxidase) in 0.01 M 
phosphate buffer, 0.15 M NaCl, 15 mM NaN3, pH 7.2 
1 mixing I storage bottle for the StreptABComplex 
30 minutes before use, prepare the StrepAB Complex as follows; 
5 ml of 0.05 M Tris I HCI, pH 7.6 was placed in the StrepABComplex mixing 
bottle 
1 drop (45 UL) of reagent A was added 
1 drop of reagent B was then added 
The bottle was mixed well and left for 30 minutes before used. 
Other staining chemicals used 
a Xylene (98.5 % ; Fisher chemical ) 
b. Ethanol ( 99 % ) 
c. 30 %Hydrogenperoxide(M=34.01 g/mol, 1L= 1.11 kg; Merck) 
d. Haematoxylin (Sigma) 
e. Ammonia (BDH) 
f. Tris ( hydroxymethyl ) ammonia ( Sigma) 
g. NaCl (99.9%; BDH) 
h. Sodium Azide (Sigma) 
i. Diaminobenzidine Tetrahydrochloride (DAB) ( 79 % ; Sigma) 
j. Bovine serum albumin (Sigma) 
Types of solutions were prepared for staining: ( Appendix C ) 
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a. 0.05 M Tris Buffered Saline pH 7.6 
b. TBS antibodies diluent 
c. DAB substrate solution 
d. PBS solution 
Methods of p53 immunohistochemical staining 
1. The sections were dried in the oven at 60 degree Celcius for 30 minutes. 
2. Then the sections were deparaffinized with xylene and the hydrated sections to water. 
3. The sections were put into 3 o/o hydrogen peroxide in methanol for 15 minutes in order to 
remove the endogenous peroxidase from the tissue. 
4. For antigen retrieval the slides were placed in a jar filled with Citrate buffer solution and 
heated in microwave oven for 5-1 Ominutes at high power (7 SOW). The slides were 
cooled with the solution to room temperature for about 20 minutes. 
5. Sections were gently rinsed with distilled water and Tris Buffered Saline (TBS) for 2 
minutes. 
6. 2-3 drops of primary antibody (Monoclonal Mouse Anti Human p53 protein; DAKO) 
was applied to the sections in a dilution of 1:50 and incubated overnight. 
7. Sections were rinsed with TBS. 
8. 2 - 3 drops of secondary antibody Biotinylated Rabbit Anti - Mouse Immunoglobulins 
(DAK.O) was applied to the sections in a dilution of 1:100 and sections were incubated 
for 30 minutes. 
9. Sections were rinsed with TBS. 
10. 2 - 3 drops of StreptAB Complex!HRP was applied to the sections in a dilution of 1: 100 
for 3 0 minutes. 
11. After 1hat sections were rinsed with TBS. 
12. 4-6 drops ofHRP substrate chromogen (Diaminobenzidine) was applied to the sections 
and incubated for 5 minutes. 
13. Sections were rinsed with tap water. 
14. Sections were then counterstained with Haris Haematoxylin for 1 dip. 
15. Then the sections were submitted to bluing process with ammonia, rehydrated, cleared 
and tnounted. 
All of the antibodies were diluted in TBS antibodies diluent. 
All sections were incubated in the room temperature. 
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Methods of Rb gene protein immunohistochemical staining 
1. The sections were dried in the oven at 60 degree Celsius for 30 mi!llrtes. 
2. Then the sections were depara:ffinized \vith xylene and hydrated sections to water. 
3. The sections were put into 3% h~drogen peroxide in methanol for 15 minutes in order to 
..... 
remove the endogenous peroxidase from the tissue. 
4. For antigen retrieval the slides were placed in a slide bath containing 400ml of working 
strength of Antigen Retrieval Glyca Solution. The slides are placed in microwave and 
turn to a rapid boil at high power of 700W to 1 OOOW for_aduration of 3 to 7 minutes. 
Then change to half the initial power and repeat the procedure and stop upon boiling and 
maintained it for 20 seconds. Repeat the same cycle for 3 to 5 times. Cool the slides with 
the Glyca solution to room temperature for about 20 minutes duration. 
5. Sections were gently rinsed with distilled water and Phosphate Buffered Saline 
(PBS) for 15 minutes. 
6. 2 - 3 drops of primary antibody (Epitope Specific Polyclonal Rabbit Antihuman 
Antibody to Retinoblastoma Protein BioGenex) was applied to the sections in a dilution 
of 1:50 and incubated for 30 minutes. 
8. Sections were rinsed with PBS followed by subsequent wash with TBS. 
9. 2 - 3 drops of secondary antibody Biotinylated Goat Anti Rabbit Immunoglobulins 
(DAKO No. E432) was applied to the sections in a dilution of 1:100 and sections were 
incubated for 30 minutes. 
10. Sections were rinsed with TBS. 
11. 2 - 3 drops of StreptABComplexiHRP was applied to the sections in a dilution of 1:100 
for 30 minutes. 
12. After that sections were rinsed with TBS. 
13. 4-6 drops ofHRP substrate chromogen (Diaminobenzidine) was applied to the sections 
and incubated for 5 minutes. 
14. Sections were rinsed with tap water. 
15. Sections were then counterstained with Haris Haematoxylin for 1 dip. 
16. Then the sections were subjected to bluing process with ammonia, rehydrated, cleared 
and mounted. 
All of the antibodies were diluted in TBS antibodies diluents. 
All sections were incubated in the room temperature. 
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Types of solutions prepared for staining 
1. 0.05 M Tris Buffered Saline pH 7.6 
a Tris stock 0.05 :tvl pH 7.6: 
Tris - 60.55 gm 
Distilled water - 980 m1 
·:;, 
IN HCL was added to give pH 7.6 and the mixture was made up to 1 Liter 
with distilled water. 
b. NaCl stock: 
NaCl (99.5 %) -87.66 gm 
Distilled water - 1 Liter 
c. Both solutions were mixed. Equal parts of a and b solutions (1 00 m1 
each) was mixed and made up to 1 Liter with distilled water. 
2. TBS antibodies Diluent 
TBSpH7.6 
Sodium azide 
Bovine Serum Albumin 
- 100 ml 
-0.1 gm 
-l.Ogm 
Above ingredients were mixed well 
3. DAB substrate solution 
a DAB -6.0mg 
b. 0.05 M TBS pH 7.6 - 10 m1 
c. 3% hydrogen peroxide - 0.1 m1 
d. DAB was dissolved in TBS and then was filtered. This product was added just 
before used. 
4. PBS substrate solution 
a Dissolve 1 tablet in 200 ml of water to obtain; 0.01 M Phosphate Buffer, 
0.0027 M Potassium Chloride and 0.137 M Sodium Chloride 
b. Now the solution is at pH 7.4 at 25 degree Celcius 
c. Store solution at 0 - 5 degree Celcius 
d. Discard if turbidity develops 
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The microscopy and the scoring method 
The immunostained sections were examined under light microscope. Tmnour suppressor 
protein imm.ooo-positivity was interpreted as number of cases eipressing low or high. 
positivity. The deduction of p53 and Rb index were based on nuclear and 
intracytoplasmic positive imm~~staining respectively. The counting is standardized and 
the evaluation is based on an average of 10 high power fields, using a X 40 objective and 
a Xl 0 ocular lens of a Nikon Y2 microscope. This is a semi--quantitative analysis, which 
is inter-observer dependent. The intensity of staining was not included as criteria in the 
evaluation. 
The counting system is based on the scoring system suggested by Dowell & Hall (1994). 
If the case showed more than 20 % of cells positively stained, they are scored as 'high 
positivity' and those with less than 20 % of the cells positively stained, they are scored 
'low~ positivity. 
Statistical Analysis 
The data was statistically analyzed using SPSS univariate chi-square test. Chi-square test 
was employed to compare whether there was any difference in proportion (Dawson-
Saunders & Trapp, 1994) between low and high positivity in he immnuno staining for 
p53 and Rb protein between the different groups of cervical lesions studied. 
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4.RESULTS 
A total of 152 cases were included in this study. Of these 68 (44%) were preinvasive lesions 
[CIN change.s]~ 62 (40.8o/o) were qancerous. Of the cancerous lesions, squamous cell_ carcinoma 
were 52 (82.8%) and adenocarcinoma makes up the rest. The majority of the squamous cell 
carcinoma is of the keratinising variant (§5.3%). The proportion of the cases is as in table 4 and 
.. ' 
pie chart in figure 8 below. 
Table 4 : The proportion of the cases in this study 
Case Group Designation of Case Group Number of cases 
-Control 1 22 
LSIL 2 41 
HSIL 3 27 
SCCK 4 34 
SCCNK 5 18 
ADENOCARCINOMA 6 lO 
Key: LSU..=Low grade intraepithelial lesions, HSll..= High grade intmepithelial lesions, sec K=Keratinising squamous cell 
carcinoma, sec NK. = NonKeratinising Squamous Cell Carcinoma 
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Figure 8 : Pie chart exhibiting percentages among different cervical lesions in this study 
SCCK 
25% 
Adsno + Others LSIL 
21% 
ltJLSIL 
SIHSIL 
GSCCK 
EJSCCNK 
I!!Adeno +Others 
Pie chart exhibiting percentages among different cervical 
lesaons in this study. 
Table 5: Racial distribution according to case groups studied in%. 
Control LSIL HSIL Squamous Adenocarcinoma 
Race Carcinoma & Others 
( SCC & SCCNK) 
1\blay 18 20 16 47 5 
(82%) (49%) (59%) (90%) (50%) 
Chinese 2 21 11 3 5 
(9%) (51%) (41%) (6%) (50%) 
Siamese 2 2 
& Indian (9%) (4%) 
Total 22 41 27 52 10 
(100%) (100%) (100%) (100%) (100%) 
Table 6: The Dermography Of The Patients 
Age/years Control LSll.. HSIL sec Adenocarcinoma 
JSCCK and SCCN~{] 
< 30 0 1 0 0 0 
31-39 6 6 6 0 3 
40-49 8 17 7 21 3 
50-59 4 12 7 14 2 
60-69 4 4 7 15 2 
70-79 0 0 0 2 0 
>80 0 1 0 0 0 
TotaJ 22 41 27 52 10 
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The Histology of various precursor and invasive cervical cancer lesions 
a) Normal histology of the cervix 
. · · :· ·:· ··.-·. 
b) Koilocytic atypia 
c) Severe dysplasia 
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Results for p53 immunohistochemical staining 
Iu the evaluation of the total 152 cases studied, only 15.8% of the cases detnonstrat~d high p53 
index and 84.2% showed the low p53 index (Figure 9). On comparing each individual group 
with the control group, the SCCNK gro"!W was found to exhibit high positivity p53 index which 
is statistically significant (p = 0. 001 ). In the Control group, 9.1% of them showed p5 3 positivity 
while 55.6% of the SCCNK showed p53 positive. There was no case of Adenocarcinoma 
exhibiting p53 positivity. The distribution ofp53 index among all cases are shown in Figure 9. 
Figure 9: The distribution ofp53 index 
Distribution in percentage of low and high p53 index among 
total cases studied. 
% low positivity 
84.2% 
% high positivity 
15.8% 
,,',,:"·· ·">,'>":'·. ·:"'·'··. :· p %. ili~H·'pbsiti~itY . 
....... ... . · • . 
::::::: :~: . :: ~::~~ ::~:::: ::.: ~:: :.::: ::~~: :::: .. ::::: 
• p':% 'lp~.p~si1i\/"i& ,:· 
Majority of the l1igh p53 index belongs to the Squamous Carcinoma group; SCCNK(41.7 %) and 
SCCK (29.2%) (Figure 10 and Figure 11 ). 
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Figure 10 : Bar diagram displaying % p53 high positivity distribution among different case 
groups studied . _ 
p53 index vs percentages of cervical tesons 
' 
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Figure 11: The percentage of high p53 staining 
Distribution% of p53 high positivity index among cervical 
lesions studied 
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Table 7: Shovring the percentage ifp53 positivity According to Lesions And the p Value 
Lesions Percentage of p53 positivity I p value 
Invasive cancer 71% . p=O.OOS 
I Preinvasive cancer 21% P> 0.005 
• ' 
The histology of p53 staining 
Figure 12: The p53 staining- negative staining of normal cervix 
Figure 13: Positive staining of p53 in severe dysplasia (CINlll) 
The positive cells are 
indicated by dark 
staining of the nuclei 
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Figure 15: Positive P53 immunostaining in Large Cell Keratinising SCC (X40) 
Results for Rb immunohistochemical staining 
A total of 152 cases were subjected to Rb staining using immunohistochemsistry and scored in a 
similar manner as done to p53 staining. 65.8% of the cases were positve . The positive stained 
cells showed brown granular cytoplasmic staining. There was an upward trend of Rb high 
positivity index observed between each group. The Adenocarcinoma group showed lower Rb 
positivity compared to the Control group. The ·results is shown in Figure 12. 
Figure 16 : The distribution of Rb positivity in the cervical lesions studied 
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The chi-square test was used and the comparison was valid among the Control group and 
the. other.. 3 groups~ LS~:r.SCCK and SCCNK. The difference-het\veen .Contr-Ol-and LSIL -- --
is significant (p=0.321). The high Rb positivity index for both is 54.5% and 41.5% 
t 
respectively. Comparing the lesionaf groups and the control group, the p values are 
shown in table 8. The p values were statistically significant in SCCK (p=0.002) and 
SCCNK (p= 0.018). 
Figure 17 : Proportions of Rb index in percentage among total cases studied. 
Pecentages of high Rbindex to the total case studied 
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TableS: The percentage ofRb positivity According to Lesions And the p Value 
Lesions Percentage of Rb index p value 
LSIL 41.5% p>0.005 
Squamous cancers >88% p< 0.005 
(SCCK and SCCNK) 
Adenocarcinoma 30% p>O.OOS 
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Sta tistical correlation between p53 immunostaining and Rb protein immunostaining 
Correlating between the two tumour suppressor gene markers, the proportion of cases 
(SJ .3 %)_demons.tr.ating_hoth ..higl'l-positiYi1y-iRde."-· for -pSJ-and-. Rb. -f>re-teffi-s-··Were-·~· 
statistically significant with p values of 0.048 (Table 9). 
Table 9 : The cross-tabulation below displays chi-square output correlating the proportion 
between % p53 index and % Rb index 
Retinobiastoma gene 
Total 
. 
Low positivity High positivity 
48 80 128 
p53 % low positivity 
(tumour suppressor gene) 37.5% 62.5% 100% 
4 20 24 
p53 % high positivity 
( tumour suppressor gene ) 16.7% 83.3% 100% 
Total cases with percentage 52 100 152 
positivity of p53 
34.2% 65.8% 100% 
Figure 18: Positive Rb staining in preneoplastic lesion (X40) 
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FigUI·e 19: Positive Rb protein immunostaining in Lare Cell Non keratinising SCC (xi 0 ). 
--.~-. · . .. ---- . 
Figure 20: Rb immunostaining of large cell Keratinising SCC (x40) 
Figure 21: Low Rb staining in adenocarcinoma (X40) 
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5. DISCUSSION 
Cancer of the cervix is the second cause of cancer deaths among females in Malaysia after breast 
cancer. Penang, a state which has an up~~9 date cancer registry records an annual incidence of 16 
cases per 100,000 females. For the past ~nty years Annual Reports of Ministry of Health recorded 
an average of 2200 new cases per year (Ministry of Health Annual Reports from 1980 to 2000). This 
number is higher than the speculated 16 cases per 100,000 females in this country where the 
population of females is about 10.5 million. 
Cervical cancer is a disease of the economically disadvantaged countries (Sidawy, 1997). Masood 
(1999) estimated that approximately 440,000 new cases of cervical cancers occur annually worldwide, 
and 80% of these cancers occur in developing and undeveloped countries. Cervical cancer accounts 
for 6% of all malignant tumours and 4900 deaths in the United States each year (Sidawy, 1997). 
Cervical cancer is the first solid tumour shown to be directly induced by virus (Oncology Channel, 
Oct 2000). HPV is found in virtually all cervical carcinomas and their precursors. Deaths from 
cervical cancer account for 2% of all cancer deaths and 18% of all gynaecologic cancer deaths 
(Sidawy, 1997). In Mexico, death from cervical cancer accounts for 25% of all cancer - related deaths 
in females. The incidence rates of cervical cancer in several cities in Latin America, are among the 
highest worldwide, probably due to a high frequency of risks factors and a low screening coverage for 
the cancer (Eluf-Neto & Nascimento, 2001) 
Socioeconomic factors play an important role in pathogenesis of the cancer the cervix. This is 
depicted by its high incidence in under developed or developing nations. The contributing factor is 
lack of proper and regular screening programs in these countries. 
In our study, 90% of the invasive squamous cell cancers are seen in the Malays, an ethnic group 
known to be in the lower economic bracket than the Chinese. The total family income for the Malays 
is approximately 1000 Ringgit less than the Chinese. This finding is concurrent with a higher number 
ofHSll.. cases seen in the Malays (59%) compared to those seen in the Chinese (41%). The reverse is 
true for the lower category of preinvasive lesions, LSll... Another possible inference is the Chinese 
having better awareness regarding the cervical screening programme, better accessibility to health 
care centers and has higher motivation for early screening. The Chinese community mostly resides in 
the urban or suburban areas as compared to the Malays. 
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15% to 70% of CIN cases would eventually develop into sinister invasive cervical cancer if left 
untreated (Oncology Channel, Oct 2000). Projecting this knowledge of tumour progression, the low 
incidence of invasive cervical cancer among the Chinese females in our study could be due to that the 
preinvasive stage was detected via the screening programme. 
Conventional Adenocarcinoma, Adenosquamous Carcinoma and Neuroendocrine Carcinoma account 
for a very low percentage both among the Malays (5%) and Chinese (12o/o) patients. In this study 
Adenocarcinoma of the cervix were noted in the Chinese, however the number of cases were small for 
coherent statistical analyis. Adenosquamous Carcinoma, a variant which have a more aggressive 
biological behaviour (Wright eta/, 1994) was seen in the Malays, nevertheless the number was also 
small. 
Aggressiveness of cervical cancers depends on a number of factors. The most important of those is the 
HPV strains. Thomas et al. (2000) conducted a study on 75 women with invasive cervical cancer in 
Bangkok, Thailand between September 1991 and September 1993. Using PCR based assay, they 
typed specific HPV DNA in cervical scrapings. Seventy nine percent (79%) of the invasive cancers 
were HPV types 16 and 18 while only 57% of preinvasive cervical cancer lesions (CIN changes) had 
those strains, They did not find HPV strains of types 31/33/35/39 in any of those invasive lesions. The 
authors concluded that the invasive cancers are due to type 16 and 18 than due to other strains. In 
another study in Japan by Nagai eta/. (2001), also utilizing PCR based assay, further enhanced the 
understanding that not only HPV 16 implicated in invasive cervical cancers, the DNA of this HPV 
strain was seen in Squamous Cell Carcinoma and Adena-squamous Carcinoma On the contrary, 
HPV 18 was proven to be the aetiological viral subtype for Conventional Adenocarcinoma. In our 
previous study using cocktail HPV detected by in situ Hybridization (Salina Awang and Nor Hayati 
Othman, 1997) we noted that HPV prevalence in invasive cervical cancers among female patients 
seeking treatment at Hospital Universiti Sains Malaysia was 24%. This figure is in marked 
discrepancy compared to the figure of 75.4% in a study done in Kuala Lumpur by Padmanathan et al 
using PCR essay (Padmanathan, Y adav Gregory 1996). 
HPV infection is a sexually transmitted disease with a peak prevalence of infection in 22 - 25 year old 
women. The prevalence of infection decreases with age, suggesting that infection resolves through 
host immune responses (Sidawy, 1997). Stoler (1997) deduced from his epidemiological study that 
having the highest prevalence of LSIL is seen in women in early twenties and HSlL in late twenties 
and early thirties. In our study we do not see significant difference in the ages of women having LSIL 
and HSIL. The probable reasons of such findings could be due to lack of awareness for cervical smear 
screening programme, relatively low frequency in premarital sexual activity or commencing sexual 
3() 
activity at a later age. In the west, there is a trend towards earlier age for all of these stages:t 
supposedly related to early exposure of sexual activity (Stoler, 1997). The age of the patients with 
invasive cancers is in concordance with those seen by other authors. A sporadic case (one patient) of 
an 80 year old woman having LSTI... in our series is an interesting observation. Weaker immune 
response among the elderly predisposes tqem to a greater risk of HPV infection (Oncology Channel, 
2000). This is only possible provided ·.ffiey are sexually active. These women who lack post 
menopausal oestrogen have a higher than average risk for succumbing to HPV infection. 
Subsequently, exhibiting higher incidence of subsequent invasive cervical malignancy (Oncology 
Channnel, 2000). 
Majority of the invasive cancers that we analyzed showed high p53 positivity (71 %). They were the 
squamous cancers. This is an expected fmding as p53 is a tumour suppressor gene, which is often 
expressed in many cancers. We expected a higher percentage of positivity. Prives and Hall (1999) 
confirmed that the abnormalities of the p53 tumour suppressor gene are among the most frequent 
molecular events in human and animal neoplasia Unexpectedly we saw 9.1% of the control tissue 
showing p53 positivity, a finding higher than is seen in the LSTI.., cases and almost as high as those in 
the HSIL category. 
The statistical analysis showed a significant difference (p= 0.005) for the invasive cancer when 
compared to the control group while the pre invasive lesions when analyzed together did not show a 
significant difference (p<O.OOS) compared to the control group. There is a good correlation between 
percentage of high p53 index and the presence ofp53 mutation or degradation (Dowell, 1994). 
Surprisingly none of the adenocarcinoma were p53 positive. Adenocarcinoma as a group is more 
invasive than the squamous carcinoma. It is unfortunate that we were not able to determine which 
HPV type was responsible to cause which particular cancer. Stoler in 1997 noted that p53 index is 
highly positive in the Squamous Carcinoma closely associated with HPV 16 infection while HPV 18 
is more consistently associated with Adenocarcinoma of the cervix. HPV 18 rarely is associated with 
invasive Squamous Cell Carcinoma Similar findings were confirmed by one study in China (Lo et al, 
2001). Therefore, we could imply that the p53 index corresponds to the type specific HPV infections 
and the high p53 index is more pronounced in SCC than Adenocarcinoma. Conversely, Yang et al. 
(2001) using PCR amplification followed by restriction enzyme digestion technique~ demonstrated 
that p53 polymorphism may have a role in the development of Adenocarcinoma but not Squamous 
Cell Carcinoma. 
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The high postivity of p53 in the control group (9 .1%) is most probably due to technical false 
positivity. Other possible explanation is stabilization of p53 protein as a result from the changes in 
cellular environment other than mutation or due to over expr~ssion of p53 pr~tein following cellular 
DNA damage resulting in defective p53/m9m-2 interaction. 
Detection of p53 abnonnality proved to be a valuable tool in selecting patients with an increased 
likelihood of poor survival (Prives and Hall, 1999). Due to the limitation of this study we were not 
able to follow the progress of our patients in terms of their survival period. 
We do not think there is a coherent correlation between high p53 positivity and the ethic group. It is 
interesting to note that the majority of patients with high p53 index in our study were the Malays. 
Retinoblastome (Rb) gene is also a tumour suppressor gene. In our study we noted an increasing trend 
of Rb positivity in the Contro~ Preinvasive and Carcinoma group. Generally the positivity seen is 
higher than those seen with p53 staining. The HSTI... and the invasive cancers with the exception of 
adenocarcinoma displayed more than 77% high Rb index. This is understandable as the high risk 
HPV has E7 oncoprotein which has the ability to form inactivating complexes with the Rb protein. 
This is done when the virus protein competes the 'Rb pocket' protein (Stoler, 1997) causing 
functional inactivation of the Rb protein. As a consequence) there will be a release in host potent 
transcription factor, E2F, which is capable of activating a variety of host genes. Following which, 
there will be an exaggerated DNA synthesis and unperturbed cell cycle progression. This is as an 
influence from certain cell transcriptional factors such as Cyclin D1 which will promote a neoplastic 
growth. 
It is worrisome to note that the Control group in our series showed an unexpectedly high (54.5%) Rb 
inde~ higher than those seen in the adenocarcinoma group. It would appear that the Rb is not a 
sensitive predictor to differentiate precancerous from non neoplastic lesions. The p value of LSa and 
the control group is >0.005. Among the two different types of cancers, the squamous and the 
adenocarcinomas, only the squamous cancers depicted a significant difference when compared to the 
control group (p<O.OOS). 
Similar to p53 staining, the staining for Rb in the Adenocarcinoma group was the lowest in our series. 
3R 
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Comparing between p53 and Rb index, high Rb index is statistically significant in proportion for each 
cervical lesions studied. It could be implied that Rb index is a. more sensitive tumour suppressor index 
for analyzing cervical lesions. Both tumour suppressor indices have a role in clinical practice. High 
risk HPV is consistently found in over 90% of cervical cancers and they possess transforming viral 
oncogenes (E6 and E7). Their main mechanism of action is reduction of tumour suppressor genes p53 
I . 
and the Retinoblastoma (Rb) of the host celis. This is done by the E6 and E7 oncoproteins of the high 
risk HPV subtypes 16 and 18. The low risk HPV such as HPV6b or 11 do not exhibit such action. 
Tumour suppressor genes can be regarded as markers of aggressiveness and in predicting the 
prognosis. The application of the tumour suppressor index could be extended to cytology analysis 
especially in suspicious lesions whereby a clear diagnosis cannot be made such as ASCUS (Atypical 
Squamous Cells of Unknown Significance) and AGUS {Atypical ·otandular Cells of Unknown 
Significance). 
The knowledge of pathogenesis of cervical cancer is expanding. Herzog et al (200 1) docwnented the 
loss of heterozygosity (LOH) on chromosomes 3p which they claimed to be a common molecular 
event in invasive c~rvical cancer. This implies that more than 1 resident tumour suppressor gene is 
involved in the pathogenesis of cervical carcinoma The invasive cancers were subjected to high 
density LOH analysis. Utilizing 25 microsatellite markers, LOH was detected in 7 out of IS (47%) 
cervical carcinomas. Losses always included markers mapping to 3p22, implicating this is the si~e of 
cervical tumour suppressor genes. Further screening provides evidence that there are 2 known tumour 
suppressor genes, TbetaR-TI and FIDT on chromosome 3p22 which are involvect in cervical 
carcinogenesis. The LOH identification is our next step in research on cancer of the cervix. 
Detennination of HPV DNA via viral load study employing the second-generation hybrid capture test 
' 
is a new and easier technique to identify HPV DNA in cervical tissues (Barlam, 2000). This is the 
plan for the very near future in Pathology Deparbnent, USM. Instead of identifying precursor cells 
CINl,C:IN 1l and CIN lll, the move now is to use the presence of HPV DNA in cervical smear cells as 
the indicator whether the women is at risk or otherwise. This 1est may one day enable women to do · 
self·test, improving the detection rates among women with limited access to health care or reluctance 
1o undergo pelvic examination (Barlam, 2000). 
In our opinion, screening women with the conventional Pap smear could be coupled with staining the 
cervical scrapes for tumour suppressor genes in order to enhance detection on the likelihood a woman 
will get cancer or otherwise. 
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